PHARMING GROUP NV (PHARM.AS) Stock Price, Forecast & Analysis
Europe - AMS:PHARM - NL0010391025 - Common Stock
PHARM.AS Key Statistics, Chart & Performance
The current stock price of PHARM.AS is 1.395 EUR. In the past month the price increased by 12.5%. In the past year, price increased by 89.02%.
PHARM.AS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 67.74 | 44.96B | ||
| 1AE.DE | ARGENX SE | 67.72 | 44.95B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.95B | ||
| 2X1.DE | ABIVAX SA | N/A | 6.90B | ||
| ABVX.PA | ABIVAX SA | N/A | 6.88B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.77B | ||
| 5CV.DE | CUREVAC NV | 5.17 | 1.01B | ||
| NANO.PA | NANOBIOTIX | N/A | 820.63M | ||
| PHIL.MI | PHILOGEN SPA | 20.79 | 692.99M | ||
| IVA.PA | INVENTIVA SA | N/A | 517.80M | ||
| FYB.DE | FORMYCON AG | N/A | 341.03M | ||
| VLA.PA | VALNEVA SE | N/A | 314.28M |
Related stock screener links
About PHARM.AS
Company Profile
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 426 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Company Info
PHARMING GROUP NV
Darwinweg 24
Leiden ZUID-HOLLAND NL
Employees: 404
Phone: 31715247400
PHARMING GROUP NV / PHARM.AS FAQ
What does PHARMING GROUP NV do?
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 426 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Can you provide the latest stock price for PHARMING GROUP NV?
The current stock price of PHARM.AS is 1.395 EUR. The price increased by 1.97% in the last trading session.
What is the dividend status of PHARMING GROUP NV?
PHARM.AS does not pay a dividend.
How is the ChartMill rating for PHARMING GROUP NV?
PHARM.AS has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
How many employees does PHARMING GROUP NV have?
PHARMING GROUP NV (PHARM.AS) currently has 404 employees.
PHARM.AS Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to PHARM.AS. When comparing the yearly performance of all stocks, PHARM.AS is one of the better performing stocks in the market, outperforming 97.34% of all stocks.
PHARM.AS Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to PHARM.AS. PHARM.AS has an average financial health and profitability rating.
PHARM.AS Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.84% | ||
| ROE | -3.42% | ||
| Debt/Equity | 0.5 |
PHARM.AS Forecast & Estimates
14 analysts have analysed PHARM.AS and the average price target is 1.95 EUR. This implies a price increase of 39.66% is expected in the next year compared to the current price of 1.395.
For the next year, analysts expect an EPS growth of 308.75% and a revenue growth 18.75% for PHARM.AS